famotidine has been researched along with lubiprostone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukuda, H; Hayashi, T; Imai, T; Kawada, K; Miyamura, M; Morita, Y; Ohta, T; Tanaka, K | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for famotidine and lubiprostone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for famotidine and lubiprostone
| Article | Year |
|---|---|
Effect of lubiprostone on vinca alkaloid-induced constipation in patients with hematological malignancies: a propensity score-matched analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chloride Channel Agonists; Constipation; Cyclophosphamide; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Famotidine; Female; Hematologic Neoplasms; Humans; Laxatives; Lubiprostone; Lymphoma; Magnesium Oxide; Male; Middle Aged; Narcotics; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Propensity Score; Proton Pump Inhibitors; Retrospective Studies; Risk Factors; Sennosides; Vinca Alkaloids; Vincristine | 2020 |